Eli Lilly's Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, Eli Lilly announced the topline results from its SURPASS-CVOT trial/NCT04255433, which is a phase III study that investigated the cardiovascular benefits of its dual-agonist drug Mounjaro (tirzepatide). The ~5-year trial involved 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease, comparing once-weekly Mounjaro against Trulicity (dulaglutide), which is another GLP-1 RA from Eli Lilly.

The study achieved its primary endpoint by demonstrating Mounjaro’s noninferiority to Trulicity in reducing the 3 major adverse cardiovascular events/MACE-3, which include cardiovascular death, heart attack, or stroke. Overall, Mounjaro reduced the MACE-3 by 8% compared to Trulicity. Analysts from William Blair and Citi expressed disappointment that the trial did not show superiority over Trulicity.

Mounjaro reduced MACE-3 by an estimated 28% and all-cause mortality by 39% when compared to a placebo. Additionally, Mounjaro led to greater improvements in A1C, weight, and cardiovascular biomarkers. A significant finding was a 16% lower rate of all-cause mortality compared to Trulicity, as well as greater kidney protection

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the US, Europe, China, Japan, and internationally.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.